Image generated by Wall-E

Imagine an emerging and novel cancer agent which could be deployed as a versatile and multi-functional tool, akin to the dual-purpose nature of the novel bispecific ADC, with added bells and whistles.

Just as a Swiss army knife combines multiple tools in a single compact form, this new ADC represents an innovative convergence of two targets, two payloads, one mission.

Can it be done?

At least one company believes so – enough to collaborate on building a brand new product from scratch…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by